Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: A perspective from the Hunter Outcome Survey (HOS)

Molecular Genetics and Metabolism

Volumn 103, Issue 2, 2011, Pages 113-120

  Burton, Barbara K ^a   Whiteman, David A H ^b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SHIRE   (United States)

^c Shire AG   (Switzerland)

Author keywords

Antibody; Enzyme replacement therapy; Hunter syndrome; Idursulfase; Infusion related reaction; Mucopolysaccharidosis type II

Indexed keywords

IDURONATE 2 SULFATASE; IMMUNOGLOBULIN G ANTIBODY;

ABDOMINAL PAIN; ABNORMAL RESPIRATORY SOUND; ADOLESCENT; ADULT; AGGRESSION; AGITATION; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ANTIBODY BLOOD LEVEL; ANXIETY; ARTICLE; BACTERIAL INFECTION; BLOOD PRESSURE; BODY TEMPERATURE; CARPAL TUNNEL SYNDROME; CATHETER SITE PAIN; CHILD; CHILL; COMPLEX PARTIAL SEIZURE; CONJUNCTIVAL HYPEREMIA; CONSTIPATION; CONVULSION; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG USE; ENZYME REPLACEMENT; ERYTHEMA; EXTERNAL OTITIS; FACE EDEMA; FEVER; FLUSHING; HEARING IMPAIRMENT; HUMAN; HUNTER SYNDROME; HYPERSENSITIVITY; HYPOTENSION; INCIDENCE; INFECTION; INFUSION RELATED REACTION; INFUSION SITE SWELLING; JOINT SWELLING; LACERATION; LIMB ABSCESS; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALAISE; MEDICATION ERROR; NECK PAIN; NOSE CONGESTION; OBSTRUCTIVE AIRWAY DISEASE; OTALGIA; OTITIS MEDIA; OTORRHEA; PNEUMONIA; POOR VENOUS ACCESS; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; RHINORRHEA; SIDE EFFECT; SINUSITIS; SKIN ULCER; SWELLING; TACHYCARDIA; TRACHEA STENOSIS; TREMOR; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING; WHEEZING; WOUND; WOUND INFECTION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-ALLERGIC AGENTS; ANTIBODIES, NEUTRALIZING; CHILD; CHILD, PRESCHOOL; DATA COLLECTION; DATABASES, FACTUAL; ENZYME REPLACEMENT THERAPY; HUMANS; HYPERSENSITIVITY; IDURONATE SULFATASE; INCIDENCE; INFANT; MUCOPOLYSACCHARIDOSIS II; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79956262492     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.02.018     Document Type: Article

References (35)

1. Muenzer J., Gucsavas-Calikoglu M., McCandless S.E., Schuetz T.J., Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II. Mol. Genet. Metab. 2007, 90:329-337.
2. Muenzer J., Wraith J.E., Beck M., Giugliani R., Harmatz P., Eng C.M., Vellodi A., Martin R., Ramaswami U., Gucsavas-Calikoglu M., Vijayaraghavan S., Wendt S., Puga A.C., Ulbrich B., Shinawi M., Cleary M., Piper D., Conway A.M., Kimura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II. Genet. Med. 2006, 8:465-473.
3. Schiffmann R., Kopp J.B., Austin H.A., Sabnis S., Moore D.F., Weibel T., Balow J.E., Brady R.O. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001, 285:2743-2749.
4. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., Desnick R.J. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N. Engl. J. Med. 2001, 345:9-16.
5. Zimran A., Elstein D., Levy-Lahad E., Zevin S., Hadas-Halpern I., Bar-Ziv Y., Foldes J., Schwartz A.J., Abrahamov A. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 1995, 345:1479-1480.
6. Kishnani P.S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W.L., Leslie N., Levine J., Spencer C., McDonald M., Li J., Dumontier J., Halberthal M., Chien Y.H., Hopkin R., Vijayaraghavan S., Gruskin D., Bartholomew D., van der Ploeg A., Clancy J.P., Parini R., Morin G., Beck M., De la Gastine G.S., Jokic M., Thurberg B., Richards S., Bali D., Davison M., Worden M.A., Chen Y.T., Wraith J.E. Recombinant human acid alpha-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007, 68:99-109.
7. Wraith J.E., Clarke L.A., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Swiedler S.J., Kakkis E.D., Braakman T., Chadbourne E., Walton-Bowen K., Cox G.F. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase. J. Pediatr. 2004, 144:581-588.
8. Harmatz P., Giugliani R., Schwartz I., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Yu Z.F., Wittes J., Berger K.I., Newman M.S., Lowe A.M., Kakkis E., Swiedler S.J. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr. 2006, 148:533-539.
9. Miebach E. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders. Int. J. Clin. Pharmacol. Ther. 2009, 47:S100-S106.
10. Brooks D.A., Kakavanos R., Hopwood J.J. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol. Med. 2003, 9:450-453.
11. Sampson H.A., Munoz-Furlong A., Campbell R.L., Adkinson N.F., Bock S.A., Branum A., Brown S.G., Camargo C.A., Cydulka R., Galli S.J., Gidudu J., Gruchalla R.S., Harlor A.D., Hepner D.L., Lewis L.M., Lieberman P.L., Metcalfe D.D., O'Connor R., Muraro A., Rudman A., Schmitt C., Scherrer D., Simons F.E., Thomas S., Wood J.P., Decker W.W. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J. Allergy Clin. Immunol. 2006, 117:391-397.
12. Lieberman P. Biphasic anaphylactic reactions. Ann. Allergy Asthma Immunol. 2005, 95:217-226.
13. Richards S. Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders. Clin. Appl. Immunol. Rev. 2002, 2:241-253.
14. Kakavanos R., Turner C.T., Hopwood J.J., Kakkis E.D., Brooks D.A. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet 2003, 361:1608-1613.
15. Rosenberg M., Kingma W., Fitzpatrick M.A., Richards S.M. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999, 93:2081-2088.
16. Clarke L.A., Wraith J.E., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Sidman M., Kakkis E.D., Cox G.F. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009, 123:229-240.
17. Myozyme® prescribing information 6829 (01/09), Genzyme Corporation, Cambridge, MA, USA.
18. Hunt S.V. Perspectives from B cell immunology: fact and fancy. Int. J. Clin. Pharmacol. Ther. 2009, 47(Suppl 1):S86-S99.
19. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421-3452. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
20. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders. Jama 1999, 281:249-254.
21. Bach G., Eisenberg F., Cantz M., Neufeld E.F. The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc. Natl Acad. Sci. USA 1973, 70:2134-2138.
22. Young I.D., Harper P.S. Mild form of Hunter's syndrome: clinical delineation based on 31 cases. Arch. Dis. Child. 1982, 57:828-836.
23. Young I.D., Harper P.S. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev. Med. Child Neurol. 1983, 25:481-489.
24. Jones S.A., Almassy Z., Beck M., Burt K., Clarke J.T., Giugliani R., Hendriksz C., Kroepfl T., Lavery L., Lin S.P., Malm G., Ramaswami U., Tincheva R., Wraith J.E. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey. J. Inherit. Metab. Dis. 2009, 32:534-543.
25. Wraith J.E., Scarpa M., Beck M., Bodamer O.A., De Meirleir L., Guffon N., Meldgaard Lund A., Malm G., Van der Ploeg A.T., Zeman J. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur. J. Pediatr. 2008, 167:267-277.
26. Elaprase® prescribing information HU-700 (10/07), Shire HGT Inc. Cambridge, MA, USA.
27. Bagewadi S., Roberts J., Mercer J., Jones S., Stephenson J., Wraith J.E. Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively. J. Inherit. Metab. Dis. 2008, 31:733-737.
28. Burton B.K., Wiesman C., Paras A., Kim K., Katz R. Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses. Mol. Genet. Metab. 2009, 97:234-236.
29. Wraith J.E., Beck M., Giugliani R., Clarke J., Martin R., Muenzer J. Initial report from the Hunter Outcome Survey. Genet. Med. 2008, 10:508-516.
30. US FDA Center for Drug Evaluation and Research Guidance for Industry: Bioanalytical Methods Validation May 2001.
31. ICH, Q2(R1): "Validation of Analytical Procedures: Text and Methodology" November 2005.
32. EMEA. "ICH Topic Q2B: Validation of Analytical Procedures: Methodology (CPMP/ICH/281/95), ICH Topic Q2B, Step 4 Consensus Guideline" November 1996.
33. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., Parish T., Scott G., Shankar G., Shores E., Swanson S.J., Taniguchi G., Wierda D., Zuckerman L.A. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Meth. 2004, 289:1-16.
34. Burton B.K., Guffon N., Roberts J., van der Ploeg A.T., Jones S.A. Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey. Mol. Genet. Metab. 2010, 101:123-129.
35. Muenzer J., Beck M., Eng C.M., Escolar M.L., Giugliani R., Guffon N.H., Harmatz P., Kamin W., Kampmann C., Koseoglu S.T., Link B., Martin R.A., Molter D.W., Munoz Rojas M.V., Ogilvie J.W., Parini R., Ramaswami U., Scarpa M., Schwartz I.V., Wood R.E., Wraith E. Multidisciplinary management of Hunter syndrome. Pediatrics 2009, 124:e1228-e1239.